Boston, San Diego, and Jupiter, Florida, August 2024 — Ligand Pharmaceuticals, a leading biopharmaceutical company, is pleased to announce the appointment of Marj Fackovec as the new Head of People Operations. In this role, Marj will oversee the company’s HR operations across multiple locations, driving strategic initiatives to enhance employee engagement, talent management, and operational efficiency.
Marj Fackovec most recently served as the Head of US Human Resources at BioLineRx, where she led HR operations for the company’s US division. During her tenure, she played a crucial role in shaping HR strategies, focusing on the healthcare sector, and driving key initiatives that supported the company’s growth.
Before joining BioLineRx, Marj was the Chief People Officer at Clarion | A Life Sciences Consultancy. In this role, she was instrumental in managing HR functions, including mergers and acquisitions, and implementing strategies to support the company’s expansion in the life sciences sector.
Marj also held the position of Head of HR US at Oncopeptides, Inc., where she designed and established the HR function in the US, supporting the company’s growth from pre-launch to commercialization. She was responsible for recruiting, onboarding, and building a vibrant people-centric culture.
In her earlier career, Marj worked at MilliporeSigma as a Senior HR Business Partner and Sr. Manager HR Shared Services. Over her five years at the company, she provided strategic HR guidance, supported organizational development, and led change management initiatives during significant mergers and acquisitions.
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing or acquiring technologies that aid pharmaceutical companies in discovering and developing medicines. The company’s business model is designed to create value for stockholders through a diversified portfolio of biotech and pharmaceutical product revenue streams, supported by an efficient and low-cost corporate structure. Ligand aims to provide investors with a unique opportunity to participate in the biotech industry with a diversified and lower-risk business approach compared to a typical biotech company.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
